| Bioactivity | BIIL-260 is a potent and long-acting orally active leukotriene B(4) receptor LTB4 antagonist, with anti-inflammatory activity. BIIL-260 interacts with the LTB4 receptor in a saturable, reversible, and competitive manner, has high affinity to the LTB4 receptor on isolated human neutrophil cell membranes with Ki values of 1.7 nM[1]. |
| Target | Ki: 1.7 nM (LTB4 receptor) |
| Invitro | BIIL-260 potently inhibits LTB4-induced intracellular Ca2+ release in human neutrophils with IC50 value of 0.82 nM. MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> BIIL-260 相关抗体: |
| CAS | 204974-93-6 |
| Formula | C30H30N2O3 |
| Molar Mass | 466.57 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Birke FW, et al. In vitro and in vivo pharmacological characterization of BIIL 284, a novel and potent leukotriene B(4) receptor antagonist. J Pharmacol Exp Ther. 2001 Apr;297(1):458-66. |